Research Paper Volume 16, Issue 7 pp 6163—6187

KIF3C: an emerging biomarker with prognostic and immune implications across pan-cancer types and its experiment validation in gastric cancer


Figure 7. Correlation analysis of KIF3C to the immune checkpoint, TIDE score, MSI, and IPS. (A) PD-1, (B) CTLA4, (C) LMTK3, (D) HAVCR2. (E) TIDE score between KIF3C high- and low-expression expression groups. (F) MSI Score. (G) The IPS, (H) IPS-PD-1/PD-L1/PD-L2, (I) IPS-CTLA4, and (J) IPS-PD-1/PD-L1/PD-L2 + CTLA4.